1
|
Hernandez-Patlan D, Solis-Cruz B, Latorre JD, Maguey-Gonzalez JA, Castellanos-Huerta I, Beyssac E, Garrait G, Vázquez-Durán A, López-Arellano R, Méndez-Albores A, Hargis BM, Tellez-Isaias G. Evaluation of the Antimicrobial Activity of a Formulation Containing Ascorbic Acid and Eudragit FS 30D Microparticles for the Controlled Release of a Curcumin-Boric Acid Solid Dispersion in Turkey Poults Infected with Salmonella enteritidis: A Therapeutic Model. Int J Mol Sci 2023; 24:16186. [PMID: 38003375 PMCID: PMC10671343 DOI: 10.3390/ijms242216186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2023] [Revised: 11/06/2023] [Accepted: 11/08/2023] [Indexed: 11/26/2023] Open
Abstract
The selection of components within a formulation or for treatment must stop being arbitrary and must be focused on scientific evidence that supports the inclusion of each one. Therefore, the objective of the present study was to obtain a formulation based on ascorbic acid (AA) and Eudragit FS 30D microparticles containing curcumin-boric acid (CUR-BA) considering interaction studies between the active components carried out via Fourier transform infrared spectrometry (FTIR) and differential scanning calorimetry (DSC) to minimize antagonistic effects, and comprehensively and effectively treat turkey poults infected with Salmonella enteritidis (S. enteritidis). The DSC and FTIR studies clearly demonstrated the interactions between AA, BA, and CUR. Consequently, the combination of AA with CUR and/or BA should be avoided, but not CUR and BA. Furthermore, the Eudragit FS 30D microparticles containing CUR-BA (SD CUR-BA MP) showed a limited release of CUR-BA in an acidic medium, but they were released at a pH 6.8-7.0, which reduced the interactions between CUR-BA and AA. Finally, in the S. enteritidis infection model, turkey poults treated with the combination of AA and SD CUR-BA MP presented lower counts of S. enteritidis in cecal tonsils after 10 days of treatment. These results pointed out that the use of an adequate combination of AA and CUR-BA as an integral treatment of S. enteritidis infections could be a viable option to replace the indiscriminate use of antibiotics.
Collapse
Affiliation(s)
- Daniel Hernandez-Patlan
- Laboratory 5: LEDEFAR, Multidisciplinary Research Unit, Superior Studies Faculty at Cuautitlan (FESC), National Autonomous University of Mexico (UNAM), Cuautitlan Izcalli 54714, Mexico;
- Nanotechnology Engineering Division, Polytechnic University of the Valley of Mexico, Tultitlan 54910, Mexico
| | - Bruno Solis-Cruz
- Laboratory 5: LEDEFAR, Multidisciplinary Research Unit, Superior Studies Faculty at Cuautitlan (FESC), National Autonomous University of Mexico (UNAM), Cuautitlan Izcalli 54714, Mexico;
- Nanotechnology Engineering Division, Polytechnic University of the Valley of Mexico, Tultitlan 54910, Mexico
| | - Juan D. Latorre
- Division of Agriculture, Department of Poultry Science, University of Arkansas, Fayetteville, AR 72701, USA; (J.D.L.); (J.A.M.-G.); (I.C.-H.); (B.M.H.); (G.T.-I.)
| | - Jesus A. Maguey-Gonzalez
- Division of Agriculture, Department of Poultry Science, University of Arkansas, Fayetteville, AR 72701, USA; (J.D.L.); (J.A.M.-G.); (I.C.-H.); (B.M.H.); (G.T.-I.)
| | - Inkar Castellanos-Huerta
- Division of Agriculture, Department of Poultry Science, University of Arkansas, Fayetteville, AR 72701, USA; (J.D.L.); (J.A.M.-G.); (I.C.-H.); (B.M.H.); (G.T.-I.)
| | - Eric Beyssac
- UFR Pharmacie, UMR MEDIS, Université Clermont-Auvergne, F-63001 Clermont-Ferrand, France; (E.B.); (G.G.)
| | - Ghislain Garrait
- UFR Pharmacie, UMR MEDIS, Université Clermont-Auvergne, F-63001 Clermont-Ferrand, France; (E.B.); (G.G.)
| | - Alma Vázquez-Durán
- Unidad de Investigación Multidisciplinaria L14 (Alimentos, Micotoxinas y Micotoxicosis), Facultad de Estudios Superiores Cuautitlán, Universidad Nacional Autónoma de México, Cuautitlán Izcalli 54714, Mexico; (A.V.-D.); (A.M.-A.)
| | - Raquel López-Arellano
- Laboratory 5: LEDEFAR, Multidisciplinary Research Unit, Superior Studies Faculty at Cuautitlan (FESC), National Autonomous University of Mexico (UNAM), Cuautitlan Izcalli 54714, Mexico;
| | - Abraham Méndez-Albores
- Unidad de Investigación Multidisciplinaria L14 (Alimentos, Micotoxinas y Micotoxicosis), Facultad de Estudios Superiores Cuautitlán, Universidad Nacional Autónoma de México, Cuautitlán Izcalli 54714, Mexico; (A.V.-D.); (A.M.-A.)
| | - Billy M. Hargis
- Division of Agriculture, Department of Poultry Science, University of Arkansas, Fayetteville, AR 72701, USA; (J.D.L.); (J.A.M.-G.); (I.C.-H.); (B.M.H.); (G.T.-I.)
| | - Guillermo Tellez-Isaias
- Division of Agriculture, Department of Poultry Science, University of Arkansas, Fayetteville, AR 72701, USA; (J.D.L.); (J.A.M.-G.); (I.C.-H.); (B.M.H.); (G.T.-I.)
| |
Collapse
|
2
|
Neuwirth M, Kappes SK, Hartig MU, Wagner KG. Amorphous Solid Dispersions Layered onto Pellets—An Alternative to Spray Drying? Pharmaceutics 2023; 15:pharmaceutics15030764. [PMID: 36986625 PMCID: PMC10054131 DOI: 10.3390/pharmaceutics15030764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Revised: 02/13/2023] [Accepted: 02/22/2023] [Indexed: 03/03/2023] Open
Abstract
Spray drying is one of the most frequently used solvent-based processes for manufacturing amorphous solid dispersions (ASDs). However, the resulting fine powders usually require further downstream processing when intended for solid oral dosage forms. In this study, we compare properties and performance of spray-dried ASDs with ASDs coated onto neutral starter pellets in mini-scale. We successfully prepared binary ASDs with a drug load of 20% Ketoconazole (KCZ) or Loratadine (LRD) as weakly basic model drugs and hydroxypropyl-methyl-cellulose acetate succinate or methacrylic acid ethacrylate copolymer as pH-dependent soluble polymers. All KCZ/ and LRD/polymer mixtures formed single-phased ASDs, as indicated by differential scanning calorimetry, X-ray powder diffraction and infrared spectroscopy. All ASDs showed physical stability for 6 months at 25 °C/65% rH and 40 °C/0% rH. Normalized to their initial surface area available to the dissolution medium, all ASDs showed a linear relationship of surface area and solubility enhancement, both in terms of supersaturation of solubility and initial dissolution rate, regardless of the manufacturing process. With similar performance and stability, processing of ASD pellets showed the advantages of a superior yield (>98%), ready to use for subsequent processing into multiple unit pellet systems. Therefore, ASD-layered pellets are an attractive alternative in ASD-formulation, especially in early formulation development at limited availability of drug substance.
Collapse
|
3
|
Nikam A, Sahoo PR, Musale S, Pagar RR, Paiva-Santos AC, Giram PS. A Systematic Overview of Eudragit ® Based Copolymer for Smart Healthcare. Pharmaceutics 2023; 15:pharmaceutics15020587. [PMID: 36839910 PMCID: PMC9962897 DOI: 10.3390/pharmaceutics15020587] [Citation(s) in RCA: 10] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2023] [Revised: 02/02/2023] [Accepted: 02/07/2023] [Indexed: 02/12/2023] Open
Abstract
Eudragit, synthesized by radical polymerization, is used for enteric coating, precise temporal release, and targeting the entire gastrointestinal system. Evonik Healthcare Germany offers different grades of Eudragit. The ratio of methacrylic acid to its methacrylate-based monomers used in the polymerization reaction defines the final product's characteristics and consequently its potential range of applications. Since 1953, these polymers have been made to use in a wide range of healthcare applications around the world. In this review, we reviewed the "known of knowns and known of unknowns" about Eudragit, from molecule to material design, its characterization, and its applications in healthcare.
Collapse
Affiliation(s)
- Aniket Nikam
- Department of Pharmaceutical Chemistry, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune 411018, India
| | - Priya Ranjan Sahoo
- Department of Chemistry, University of Delhi, Delhi 110007, India
- Department of Chemistry, University at Buffalo, The State University of New York, Amherst, NY 14260, USA
| | - Shubham Musale
- Department of Pharmaceutics, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune 411018, India
| | - Roshani R. Pagar
- Department of Pharmaceutics, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune 411018, India
| | - Ana Cláudia Paiva-Santos
- Department of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, 3004-531 Coimbra, Portugal
- REQUIMTE/LAQV, Group of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, 3004-531 Coimbra, Portugal
| | - Prabhanjan Shridhar Giram
- Department of Pharmaceutics, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune 411018, India
- Department of Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, NY 14214, USA
- Correspondence:
| |
Collapse
|
4
|
Al-Zoubi N, Partheniadis I, Aljaberi A, Nikolakakis I. Co-spray Drying Drugs with Aqueous Polymer Dispersions (APDs)-a Systematic Review. AAPS PharmSciTech 2022; 23:140. [PMID: 35538248 DOI: 10.1208/s12249-022-02293-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Accepted: 04/25/2022] [Indexed: 11/30/2022] Open
Abstract
Aqueous colloidal dispersions of water-insoluble polymers (APDs) avoid hassles associated with the use of organic solvents and offer processing advantages related to their low viscosity and short processing times. Therefore, they became the main vehicle for pharmaceutical coating of tablets and multiparticulates, a process commonly employed using pan and fluidized-bed machinery. Another interesting although less common processing approach is co-spray drying APDs with drugs in aqueous systems. It enables the manufacture of capsule- and matrix-type microspheres with controllable size and improved processing characteristics in a single step. These microspheres can be further formulated into different dosage forms. This systematic review is based on published research articles and aims to highlight the applicability and opportunities of co-spray drying drugs with APDs in drug delivery.
Collapse
|
5
|
Petkova D, Mihaylova D, Desseva I. Microencapsulation in food industry – an overview. BIO WEB OF CONFERENCES 2022. [DOI: 10.1051/bioconf/20224502005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
In the modern health concept, food quality is becoming more and more important. People are increasingly looking for added value to their diet through the presence of bioactive substances. Usually, the latter are sensitive molecules; they are unstable in processing and consumption. In addition, problems with unpleasant organoleptic characteristics clean labelling and high production costs can occur. To overcome these problems, a solution can be sought in microencapsulation techniques. Although these techniques have been known for a long time, nowadays their meaning and significance are gaining new dimensions. In this regard, this review aims to provide up-to-date information on currently used microencapsulation techniques, limitations, and prospects.
Collapse
|
6
|
On the feasibility of spray-dried eudragit-trehalose microparticles for enteric drug delivery. Int J Pharm 2021; 610:121264. [PMID: 34742827 DOI: 10.1016/j.ijpharm.2021.121264] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Revised: 10/28/2021] [Accepted: 10/31/2021] [Indexed: 11/21/2022]
Abstract
Enteric infections have long constituted a silent epidemic responsible for hundreds of thousands of deaths around the world every year. Because of the global rise in antibiotic-resistant bacteria and the slow development of new small-molecule antibiotics, alternatives such as bacteriophage therapy have become a much sought-after option in the treatment of enteric infections. However, the administration of therapeutics through the oral route to target gastrointestinal infections poses challenges to dosage formulation because these active ingredients, particularly relatively fragile biological entities, require protection from the stomach's harsh acids. Encapsulation of the therapeutics within a pH-responsive coating capable of surviving low pH conditions has the potential to provide such protection. In this study, we developed a spray-dried powder vehicle capable of withstanding low pH comparable to stomach conditions, using Eudragit® S100 as a protective particle coating and trehalose as a stabilizing excipient for a possible active component. A particle formation model and a monodisperse droplet chain technique were initially used to study the formation process of Eudragit-trehalose composite microparticles at different ratios and in different ratios of water-ethanol solvent, which showed formation of particles with Eudragit shells varying in thickness from 0.13 μm to 0.75 μm. Promising Eudragit-trehalose formulations were subsequently spray-dried and their survival in acidic and alkaline environments studied using a new shadowgraphic imaging method. The results demonstrated that Eudragit was capable of creating a protective shell in the particles irrespective of the type of solvent used to prepare the formulations. The trehalose cores of particles with higher than 5% w/w of Eudragit remained protected after one hour of exposure at pH 2, indicating the potential of Eudragit-trehalose formulations for enteric delivery of drugs.
Collapse
|
7
|
Jain SK, Jain AK, Rajpoot K. Expedition of Eudragit® Polymers in the Development of Novel Drug Delivery Systems. Curr Drug Deliv 2020; 17:448-469. [PMID: 32394836 DOI: 10.2174/1567201817666200512093639] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2019] [Revised: 01/10/2020] [Accepted: 04/20/2020] [Indexed: 12/16/2022]
Abstract
Eudragit® polymer has been widely used in film-coating for enhancing the quality of products over other materials (e.g., shellac or sugar). Eudragit® polymers are obtained synthetically from the esters of acrylic and methacrylic acid. For the last few years, they have shown immense potential in the formulations of conventional, pH-triggered, and novel drug delivery systems for incorporating a vast range of therapeutics including proteins, vitamins, hormones, vaccines, and genes. Different grades of Eudragit® have been used for designing and delivery of therapeutics at a specific site via the oral route, for instance, in stomach-specific delivery, intestinal delivery, colon-specific delivery, mucosal delivery. Further, these polymers have also shown their great aptitude in topical and ophthalmic delivery. Moreover, available literature evidences the promises of distinct Eudragit® polymers for efficient targeting of incorporated drugs to the site of interest. This review summarizes some potential researches that are being conducted by eminent scientists utilizing the distinct grades of Eudragit® polymers for efficient delivery of therapeutics at various sites of interest.
Collapse
Affiliation(s)
- Sunil Kumar Jain
- Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur (C.G.) 495 009, India
| | - Akhlesh K Jain
- Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur (C.G.) 495 009, India
| | - Kuldeep Rajpoot
- Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur (C.G.) 495 009, India
| |
Collapse
|
8
|
Madani F, Hsein H, Busignies V, Tchoreloff P. An overview on dosage forms and formulation strategies for vaccines and antibodies oral delivery. Pharm Dev Technol 2019; 25:133-148. [DOI: 10.1080/10837450.2019.1689402] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
9
|
Davitt CJH, Longet S, Albutti A, Aversa V, Nordqvist S, Hackett B, McEntee CP, Rosa M, Coulter IS, Lebens M, Tobias J, Holmgren J, Lavelle EC. Alpha-galactosylceramide enhances mucosal immunity to oral whole-cell cholera vaccines. Mucosal Immunol 2019; 12:1055-1064. [PMID: 30953000 PMCID: PMC7746523 DOI: 10.1038/s41385-019-0159-z] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2018] [Revised: 01/26/2019] [Accepted: 02/19/2019] [Indexed: 02/07/2023]
Abstract
Cholera is a severe diarrheal disease caused by the bacterium Vibrio cholerae (V. cholerae) that results in 3-4 million cases globally with 100,000-150,000 deaths reported annually. Mostly confined to developing nations, current strategies to control the spread of cholera include the provision of safe drinking water and improved sanitation and hygiene, ideally in conjunction with oral vaccination. However, difficulties associated with the costs and logistics of these strategies have hampered their widespread implementation. Specific challenges pertaining to oral cholera vaccines (OCVs) include a lack of safe and effective adjuvants to further enhance gut immune responses, the complex and costly multicomponent vaccine manufacturing, limitations of conventional liquid formulation and the lack of an integrated delivery platform. Herein we describe the use of the orally active adjuvant α-Galactosylceramide (α-GalCer) to strongly enhance intestinal bacterium- and toxin-specific IgA responses to the OCV, Dukoral® in C57BL/6 and BALB/c mice. We further demonstrate the mucosal immunogenicity of a novel multi-antigen, single-component whole-cell killed V. cholerae strain and the enhancement of its immunogenicity by adding α-GalCer. Finally, we report that combining these components and recombinant cholera toxin B subunit in the SmPill® minisphere delivery system induced strong intestinal and systemic antigen-specific antibody responses.
Collapse
Affiliation(s)
- Christopher J. H. Davitt
- 0000 0004 1936 9705grid.8217.cAdjuvant Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, D02 R590 Ireland
| | - Stephanie Longet
- 0000 0004 1936 9705grid.8217.cAdjuvant Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, D02 R590 Ireland
| | - Aqel Albutti
- 0000 0004 1936 9705grid.8217.cAdjuvant Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, D02 R590 Ireland ,0000 0000 9421 8094grid.412602.3College of Applied Medical Sciences, Qassim University, Buraydah, 52571 Saudi Arabia
| | - Vincenzo Aversa
- 0000000102380260grid.15596.3eSublimity Therapeutics (Holdco) Ltd, DCU Alpha Innovation Campus, Old Finglas Road, Dublin, D11 KXN4 Ireland
| | - Stefan Nordqvist
- 0000 0000 9919 9582grid.8761.8Department of Microbiology and Immunology, University of Gothenburg Vaccine Research Institute (GUVAX), University of Gothenburg, Box 435, 405 30 Gothenburg, Sweden
| | - Becky Hackett
- 0000 0004 1936 9705grid.8217.cAdjuvant Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, D02 R590 Ireland
| | - Craig P. McEntee
- 0000 0004 1936 9705grid.8217.cAdjuvant Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, D02 R590 Ireland
| | - Monica Rosa
- 0000000102380260grid.15596.3eSublimity Therapeutics (Holdco) Ltd, DCU Alpha Innovation Campus, Old Finglas Road, Dublin, D11 KXN4 Ireland
| | - Ivan S. Coulter
- 0000000102380260grid.15596.3eSublimity Therapeutics (Holdco) Ltd, DCU Alpha Innovation Campus, Old Finglas Road, Dublin, D11 KXN4 Ireland
| | - Michael Lebens
- 0000 0000 9919 9582grid.8761.8Department of Microbiology and Immunology, University of Gothenburg Vaccine Research Institute (GUVAX), University of Gothenburg, Box 435, 405 30 Gothenburg, Sweden
| | - Joshua Tobias
- 0000 0000 9919 9582grid.8761.8Department of Microbiology and Immunology, University of Gothenburg Vaccine Research Institute (GUVAX), University of Gothenburg, Box 435, 405 30 Gothenburg, Sweden
| | - Jan Holmgren
- 0000 0000 9919 9582grid.8761.8Department of Microbiology and Immunology, University of Gothenburg Vaccine Research Institute (GUVAX), University of Gothenburg, Box 435, 405 30 Gothenburg, Sweden
| | - Ed C. Lavelle
- 0000 0004 1936 9705grid.8217.cAdjuvant Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, D02 R590 Ireland ,0000 0004 1936 9705grid.8217.cCentre for Research on Adaptive Nanostructures and Nanodevices (CRANN) & Advanced Materials Bio-Engineering Research Centre (AMBER), Trinity College Dublin, Dublin 2, D02 PN40 Ireland
| |
Collapse
|
10
|
Ziaee A, Albadarin AB, Padrela L, Femmer T, O'Reilly E, Walker G. Spray drying of pharmaceuticals and biopharmaceuticals: Critical parameters and experimental process optimization approaches. Eur J Pharm Sci 2019; 127:300-318. [DOI: 10.1016/j.ejps.2018.10.026] [Citation(s) in RCA: 107] [Impact Index Per Article: 21.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2018] [Revised: 10/01/2018] [Accepted: 10/30/2018] [Indexed: 10/27/2022]
|
11
|
Kanojia G, Have RT, Soema PC, Frijlink H, Amorij JP, Kersten G. Developments in the formulation and delivery of spray dried vaccines. Hum Vaccin Immunother 2018; 13:2364-2378. [PMID: 28925794 PMCID: PMC5647985 DOI: 10.1080/21645515.2017.1356952] [Citation(s) in RCA: 47] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Spray drying is a promising method for the stabilization of vaccines, which are usually formulated as liquids. Usually, vaccine stability is improved by spray drying in the presence of a range of excipients. Unlike freeze drying, there is no freezing step involved, thus the damage related to this step is avoided. The edge of spray drying resides in its ability for particles to be engineered to desired requirements, which can be used in various vaccine delivery methods and routes. Although several spray dried vaccines have shown encouraging preclinical results, the number of vaccines that have been tested in clinical trials is limited, indicating a relatively new area of vaccine stabilization and delivery. This article reviews the current status of spray dried vaccine formulations and delivery methods. In particular it discusses the impact of process stresses on vaccine integrity, the application of excipients in spray drying of vaccines, process and formulation optimization strategies based on Design of Experiment approaches as well as opportunities for future application of spray dried vaccine powders for vaccine delivery.
Collapse
Affiliation(s)
- Gaurav Kanojia
- a Intravacc (Institute for Translational Vaccinology) , Bilthoven , The Netherlands.,b Department of Pharmaceutical Technology and Biopharmacy , University of Groningen , Groningen , The Netherlands
| | - Rimko Ten Have
- a Intravacc (Institute for Translational Vaccinology) , Bilthoven , The Netherlands
| | - Peter C Soema
- a Intravacc (Institute for Translational Vaccinology) , Bilthoven , The Netherlands
| | - Henderik Frijlink
- b Department of Pharmaceutical Technology and Biopharmacy , University of Groningen , Groningen , The Netherlands
| | | | - Gideon Kersten
- a Intravacc (Institute for Translational Vaccinology) , Bilthoven , The Netherlands.,c Division of Drug Delivery Technology, Leiden Academic Center for Drug Research , Leiden University , Leiden , The Netherlands
| |
Collapse
|
12
|
Saboo S, Tumban E, Peabody J, Wafula D, Peabody DS, Chackerian B, Muttil P. Optimized Formulation of a Thermostable Spray-Dried Virus-Like Particle Vaccine against Human Papillomavirus. Mol Pharm 2016; 13:1646-55. [PMID: 27019231 DOI: 10.1021/acs.molpharmaceut.6b00072] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Existing vaccines against human papillomavirus (HPV) require continuous cold-chain storage. Previously, we developed a bacteriophage virus-like particle (VLP)-based vaccine for HPV infection, which elicits broadly neutralizing antibodies against diverse HPV types. Here, we formulated these VLPs into a thermostable dry powder using a multicomponent excipient system and by optimizing the spray-drying parameters using a half-factorial design approach. Dry-powder VLPs were stable after spray drying and after long-term storage at elevated temperatures. Immunization of mice with a single dose of reconstituted dry-powder VLPs that were stored at 37 °C for more than a year elicited high anti-L2 IgG antibody titers. Spray-dried thermostable, broadly protective L2 bacteriophage VLPs vaccine could be accessible to remote regions of the world (where ∼84% of cervical cancer patients reside) by eliminating the cold-chain requirement during transportation and storage.
Collapse
Affiliation(s)
- Sugandha Saboo
- Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University , West Lafayette, Indiana 47907, United States
| | - Ebenezer Tumban
- Department of Biological Sciences, Michigan Technological University , Houghton, Michigan 49931, United States
| | | | - Denis Wafula
- Department of Cell Biology and Molecular Genetics, University of Maryland , College Park, Maryland 20742, United States
| | | | | | | |
Collapse
|
13
|
Fan Y, Moon JJ. Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens. WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY 2016; 9. [PMID: 27038091 DOI: 10.1002/wnan.1403] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/23/2015] [Revised: 02/10/2016] [Accepted: 02/15/2016] [Indexed: 01/15/2023]
Abstract
Bioterrorism agents that can be easily transmitted with high mortality rates and cause debilitating diseases pose major threats to national security and public health. The recent Ebola virus outbreak in West Africa and ongoing Zika virus outbreak in Brazil, now spreading throughout Latin America, are case examples of emerging infectious pathogens that have incited widespread fear and economic and social disruption on a global scale. Prophylactic vaccines would provide effective countermeasures against infectious pathogens and biological warfare agents. However, traditional approaches relying on attenuated or inactivated vaccines have been hampered by their unacceptable levels of reactogenicity and safety issues, whereas subunit antigen-based vaccines suffer from suboptimal immunogenicity and efficacy. In contrast, particulate vaccine delivery systems offer key advantages, including efficient and stable delivery of subunit antigens, co-delivery of adjuvant molecules to bolster immune responses, low reactogenicity due to the use of biocompatible biomaterials, and robust efficiency to elicit humoral and cellular immunity in systemic and mucosal tissues. Thus, vaccine nanoparticles and microparticles are promising platforms for clinical development of biodefense vaccines. In this review, we summarize the current status of research efforts to develop particulate vaccine delivery systems against bioterrorism agents and emerging infectious pathogens. WIREs Nanomed Nanobiotechnol 2017, 9:e1403. doi: 10.1002/wnan.1403 For further resources related to this article, please visit the WIREs website.
Collapse
Affiliation(s)
- Yuchen Fan
- Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.,Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA
| | - James J Moon
- Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA.,Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA.,Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA
| |
Collapse
|
14
|
Pastor M, Esquisabel A, Marquínez I, Talavera A, Pedraz JL. Cellulose acetate phthalate microparticles containing Vibrio cholerae: steps toward an oral cholera vaccine. J Drug Target 2014; 22:478-87. [PMID: 24731056 DOI: 10.3109/1061186x.2014.888071] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Oral cholera vaccine (OCV) has been recommended in some endemic areas and epidemic situations since 1999. Although safe and effective vaccines are currently on the market, the burden of transport and storage remains an issue. Herein, we report an approach to develop an alternative OCV in the form of a gastro-resistant powder. Heat-killed Vibrio cholerae (VC) was encapsulated with a spray-drying technique at different temperatures. Cellulose acetate phthalate (Aquacoat® CPD) was chosen as the core polymer and the addition of alginate was studied. The microparticles (MPs) produced were characterized by surface morphology, particle size, drug loading, antigenicity and gastro resistance. The MPs obtained were 6 µm in size and had appropriate drug content, ranging from 8.16 to 8.64%. Furthermore, antigenicity was maintained, never dropping below 85%, and enteric properties were achieved for all the formulations. Next, an in vivo study was carried out with Aquacoat® CPD MP prepared at 80 °C with and without alginate. Two different doses were assayed, 30 and 60 mg, and compared to the VC suspension. The evoked immune responses showed that alginate containing MPs, especially at the 30 mg dose, displayed values that were very similar to those of VC. In conclusion, spray-dried alginate VC MPs seem to be a promising step toward a powder-form cholera vaccination.
Collapse
Affiliation(s)
- Marta Pastor
- NanoBioCel Group, Laboratory of Pharmaceutics, University of the Basque Country, School of Pharmacy , Vitoria-Gasteiz , Spain
| | | | | | | | | |
Collapse
|
15
|
Advanced progress of microencapsulation technologies: In vivo and in vitro models for studying oral and transdermal drug deliveries. J Control Release 2014; 178:25-45. [DOI: 10.1016/j.jconrel.2013.12.028] [Citation(s) in RCA: 126] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2013] [Revised: 12/10/2013] [Accepted: 12/17/2013] [Indexed: 11/20/2022]
|
16
|
McAdams D, Chen D, Kristensen D. Spray drying and vaccine stabilization. Expert Rev Vaccines 2014; 11:1211-9. [DOI: 10.1586/erv.12.101] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
17
|
Kondo K, Niwa T, Danjo K. Preparation of sustained-release coated particles by novel microencapsulation method using three-fluid nozzle spray drying technique. Eur J Pharm Sci 2014; 51:11-9. [DOI: 10.1016/j.ejps.2013.09.001] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2013] [Revised: 07/31/2013] [Accepted: 09/02/2013] [Indexed: 11/29/2022]
|
18
|
Organic solution versus aqueous dispersion of Eudragit RS in preparation of sustained release microparticles of theophylline using spray drying. Colloids Surf B Biointerfaces 2013; 108:374-9. [DOI: 10.1016/j.colsurfb.2013.03.012] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2012] [Revised: 02/04/2013] [Accepted: 03/05/2013] [Indexed: 11/21/2022]
|
19
|
Pastor M, Pedraz JL, Esquisabel A. The state-of-the-art of approved and under-development cholera vaccines. Vaccine 2013; 31:4069-78. [PMID: 23845813 DOI: 10.1016/j.vaccine.2013.06.096] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2013] [Revised: 06/20/2013] [Accepted: 06/26/2013] [Indexed: 11/19/2022]
Abstract
Cholera remains a huge public health problem. Although in 1894, the first cholera vaccination was reported, an ideal vaccine that meets all the requirements of the WHO has not yet been produced. Among the different approaches used for cholera vaccination, attenuated vaccines represent a major category; these vaccines are beneficial in being able to induce a strong protective response after a single administration. However, they have possible negative effects on immunocompromised patient populations. Both the licensed CVD103-HgR and other vaccine approaches under development are detailed in this article, such as the Vibrio cholerae 638 vaccine candidate, Peru-15 or CholeraGarde(®) and the VA1.3, VA1.4, IEM 108 VCUSM2 and CVD 112 vaccine candidates. In another strategy, killed V. cholerae vaccines have been developed, including Dukoral(®), mORCAX(®) and Sanchol™. The killed vaccines are already sold, and they have successfully demonstrated their potential to protect populations in endemic areas or after natural disasters. However, these vaccines do not fulfill all the requirements of the WHO because they fail to confer long-term protection, are not suitable for children under two years, require more than a single dose and require a distribution chain with cold storage. Lastly, other vaccine strategies under development are summarized in this review. Among these strategies, vaccine candidates based on alternative drug delivery systems that have been reported lately in the literature are discussed, such as microparticles, proteoliposomes, LPS subunits, DNA vaccines and rice seeds containing toxin subunits. Preliminary results reported by many groups working on alternative delivery systems for cholera vaccines demonstrate the importance of new technologies in addressing old problems such as cholera. Although a fully ideal vaccine has not yet been designed, promising steps have been reported in the literature resulting in hope for the fight against cholera.
Collapse
Affiliation(s)
- M Pastor
- NanoBioCel Group, Laboratory of Pharmaceutics, University of the Basque Country, School of Pharmacy, Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain
| | | | | |
Collapse
|
20
|
López Y, Pastor M, Infante JF, Díaz D, Oliva R, Fernández S, Cedré B, Hernández T, Campos L, Esquisabel A, Pedraz JL, Perez V, Talavera A. Repeated dose toxicity study ofVibrio cholerae-loaded gastro-resistant microparticles. J Microencapsul 2013; 31:86-92. [DOI: 10.3109/02652048.2013.808278] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
21
|
An approach to a cold chain free oral cholera vaccine: in vitro and in vivo characterization of Vibrio cholerae gastro-resistant microparticles. Int J Pharm 2013; 448:247-58. [DOI: 10.1016/j.ijpharm.2013.02.057] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2012] [Revised: 02/20/2013] [Accepted: 02/27/2013] [Indexed: 11/19/2022]
|
22
|
Fernández S, Año G, Castaño J, Pino Y, Uribarri E, Riverón LA, Cedré B, Valmaseda T, Falero G, Pérez JL, Infante JF, García LG, Solís RL, Sierra G, Talavera A. Evaluation of enteric-coated tablets as a whole cell inactivated vaccine candidate against Vibrio cholerae. Travel Med Infect Dis 2013; 11:103-9. [DOI: 10.1016/j.tmaid.2012.10.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2010] [Revised: 10/04/2012] [Accepted: 10/08/2012] [Indexed: 10/27/2022]
|
23
|
Tawde SA, Chablani L, Akalkotkar A, D'Souza C, Chiriva-Internati M, Selvaraj P, D'Souza MJ. Formulation and evaluation of oral microparticulate ovarian cancer vaccines. Vaccine 2012; 30:5675-81. [PMID: 22750042 DOI: 10.1016/j.vaccine.2012.05.073] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2012] [Accepted: 05/25/2012] [Indexed: 01/08/2023]
Abstract
Ovarian cancer is the fifth most leading cause of cancer related deaths in women in the US. Customized immunotherapeutic strategies may serve as an alternative method to control the recurrence or progression of ovarian cancer and to avoid severe adverse effects of chemotherapy. In this study, a microparticulate vaccine using whole cell lysate of a murine ovarian cancer cell line, ID8 was prepared with the use of a spray dryer. These particles were designed for oral delivery using enteric polymers such as methacrylic copolymer, Eudragit(®) FS30D and hydroxyl propyl methyl cellulose acetate succinate. These particles were targeted for uptake via microfold cell (M-cell) in Peyer's patches of small intestine using M-cell targeting ligand, Aleuria aurantia lectin. The interleukins (ILs) such as IL-2 and IL-12 were added to the vaccine formulation to further enhance the immune response. The particles obtained were of 1.58±0.62 μm size with a charge of 12.48±2.32 mV. The vaccine efficacy was evaluated by administering the particles via oral route to C57BL/6 female mice. At the end of vaccination, mice were challenged with live tumor cells. Vaccinated mice showed significant (around six-fold) retardation of tumor volume in comparison to non-vaccinated animals for 3 weeks after the tumor challenge (p<0.001). The serum IgG antibody levels were found to be elevated in case of vaccinated animals in comparison to non-vaccinated group (p<0.05). Analysis of IgG1 titers (indicative of Th2 response) and IgG2a titers (indicative of Th1 response) showed a mixed Th1 and Th2 immune response in case vaccine alone and Th2 response in case of vaccine with interleukins group. Moreover, CD8+ T-cell, CD4+ T-cell and B-cell populations in different lymphatic organs were elevated in case of vaccinated mice. Thus, whole cell lysate vaccine microparticles formulated by spray drying could trigger humoral as well as cellular immune response when administered orally. Such vaccine could potentially be an effective treatment for patients with residual tumor or high tumor-relapse probability.
Collapse
Affiliation(s)
- Suprita A Tawde
- Vaccine Nanotechnology Laboratory, Department of Pharmaceutical Sciences, Mercer University, College of Pharmacy and Health Sciences, Atlanta, GA 30341, USA
| | | | | | | | | | | | | |
Collapse
|
24
|
Therapeutic strategies based on polymeric microparticles. J Biomed Biotechnol 2012; 2012:672760. [PMID: 22665988 PMCID: PMC3363323 DOI: 10.1155/2012/672760] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2011] [Revised: 02/28/2012] [Accepted: 03/13/2012] [Indexed: 01/06/2023] Open
Abstract
The development of the field of materials science, the ability to perform multidisciplinary scientific work, and the need for novel administration technologies that maximize therapeutic effects and minimize adverse reactions to readily available drugs have led to the development of delivery systems based on microencapsulation, which has taken one step closer to the target of personalized medicine. Drug delivery systems based on polymeric microparticles are generating a strong impact on preclinical and clinical drug development and have reached a broad development in different fields supporting a critical role in the near future of medical practice. This paper presents the foundations of polymeric microparticles based on their formulation, mechanisms of drug release and some of their innovative therapeutic strategies to board multiple diseases.
Collapse
|
25
|
Borgogna M, Bellich B, Cesàro A. Marine polysaccharides in microencapsulation and application to aquaculture: "from sea to sea". Mar Drugs 2011; 9:2572-2604. [PMID: 22363241 PMCID: PMC3280570 DOI: 10.3390/md9122572] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2011] [Revised: 11/18/2011] [Accepted: 11/22/2011] [Indexed: 12/15/2022] Open
Abstract
This review's main objective is to discuss some physico-chemical features of polysaccharides as intrinsic determinants for the supramolecular structures that can efficiently provide encapsulation of drugs and other biological entities. Thus, the general characteristics of some basic polysaccharides are outlined in terms of their conformational, dynamic and thermodynamic properties. The analysis of some polysaccharide gelling properties is also provided, including the peculiarity of the charged polysaccharides. Then, the way the basic physical chemistry of polymer self-assembly is made in practice through the laboratory methods is highlighted. A description of the several literature procedures used to influence molecular interactions into the macroscopic goal of the encapsulation is given with an attempt at classification. Finally, a practical case study of specific interest, the use of marine polysaccharide matrices for encapsulation of vaccines in aquaculture, is reported.
Collapse
Affiliation(s)
| | | | - Attilio Cesàro
- Department of Life Sciences, University of Trieste, Via L. Giorgieri, 1-I-34127 Trieste, Italy; (M.B.); (B.B.)
| |
Collapse
|
26
|
Formulation optimization of sustained-release ammonio methacrylate copolymer microspheres. Effects of log p and concentration of polar cosolvents, and role of the drug/copolymer ratio. Pharmaceutics 2011; 3:830-47. [PMID: 24309310 PMCID: PMC3857060 DOI: 10.3390/pharmaceutics3040830] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2011] [Revised: 10/11/2011] [Accepted: 10/27/2011] [Indexed: 11/16/2022] Open
Abstract
The objectives of this work were the formulation optimization of the preparation process parameters and to evaluate spray-dried sustained-release microspheres using ammonio methacrylate copolymer (AMC) as a polymer matrix. The effects of log P and the concentrations of the cosolvents (acetone, methyl ethyl ketone and n-butyl acetate) and different drug/copolymer ratios as independent variables on the physicochemical parameters (the W1/O emulsion viscosity, the microsphere production yield, the average particle size, the encapsulation efficiency) and the cumulative in vitro drug release as dependent variables were studied. The optimization was carried out on the basis of the 33 factorial design study. The optimization process results showed that addition of polar cosolvents proved effective, linear relationships were observed between the independent and the dependent variables. The best conditions were achieved by microspheres prepared by using a low/medium cosolvent log P, cosolvent concentration of 25-50% v/v and a drug/copolymer ratio of 1:16. The microspheres ensured sustained release with Nernst and Baker-Lonsdale release profiles.
Collapse
|